Abstract: Disclosed is a high voltage signal and low voltage signal sampling and transmission system based on a high voltage MCU, including a sampling unit, a high voltage processing unit, a communication unit and a low voltage processing unit. The sampling unit includes a bus voltage sampling module, a phase voltage detection module and an IGBT temperature detection module. The high voltage processing unit adopts the high voltage MCU, and the high voltage MCU is configured to perform state monitoring and analog-to-digital conversion on the three-way analog detection signals, and output a digital signal to the communication unit; the communication unit adopts an isolated communication unit to transmit the three-way digital signal converted by the high voltage MCU to the low voltage processing unit; the low voltage processing unit adopts a low voltage MCU to realize sampling and communication of high and low voltage sampling signals.

Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.

Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.

Abstract: A long-term in-situ observation device for the deep sea bottom supported engineering geological environment is provided, including: a sediment acoustic probe, a sediment pore water pressure probe, a three-dimensional resistivity probe, a water observation instrument, a long-term observation power supply system, a probe hydraulic penetration system, a general control and data storage transmission system, an acoustic releaser, an underwater acoustic communication apparatus, and an instrument platform. The observations include the engineering properties, physical properties, mechanical properties, and biochemical properties of a seawater-seabed interface-sediment. The engineering properties and the physical and mechanical indexes of seafloor sediments are comprehensively determined by three-dimensional measurement of seafloor resistivity and acoustic wave measurements. The physical and biochemical properties of seawater are expected to be acquired by sensors.

Abstract: A long-term in-situ observation device for the deep sea bottom supported engineering geological environment is provided, including: a sediment acoustic probe, a sediment pore water pressure probe, a three-dimensional resistivity probe, a water observation instrument, a long-term observation power supply system, a probe hydraulic penetration system, a general control and data storage transmission system, an acoustic releaser, an underwater acoustic communication apparatus, and an instrument platform. The observations include the engineering properties, physical properties, mechanical properties, and biochemical properties of a seawater-seabed interface-sediment. The engineering properties and the physical and mechanical indexes of seafloor sediments are comprehensively determined by three-dimensional measurement of seafloor resistivity and acoustic wave measurements. The physical and biochemical properties of seawater are expected to be acquired by sensors.

Abstract: A benzofuran derivative, a preparation method thereof and a use thereof in medicine are described. In particular, a benzofuran derivative as shown by general formula (I), the preparation method thereof, a pharmaceutical composition containing the derivative, and uses thereof as an EZH2 inhibitor and in the prevention and/or treatment of diseases such as tumours and cancers, etc., and in particular, uses thereof in the prevention and/or treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and synovial sarcoma, are described.

Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.

Abstract: A benzofuran derivative, a preparation method thereof and a use thereof in medicine are described. In particular, a benzofuran derivative as shown by general formula (I), the preparation method thereof, a pharmaceutical composition containing the derivative, and uses thereof as an EZH2 inhibitor and in the prevention and/or treatment of diseases such as tumours and cancers, etc., and in particular, uses thereof in the prevention and/or treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and synovial sarcoma, are described.

Abstract: The present invention relates to a benzofuran derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to the benzofuran derivative as shown by general formula (I), the preparation method thereof, a pharmaceutical composition containing the derivative, and uses thereof as an EZH2 inhibitor and in the prevention and/or treatment of diseases such as tumours and cancers, etc., and in particular, uses thereof in the prevention and/or treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and synovial sarcoma, wherein the definitions of the substituents in the general formula (I) are the same as those defined in the description.

Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

Abstract: A device for observing the changes in abyssal flow based on differential pressure measurement, includes differential pressure sensing chamber and base connected through communicating portion, controller provided inside communicating portion, floating body and releasing device. Floating body is located on differential pressure sensing chamber and retracted through releasing device. Sensing chamber includes ambient water pressure chamber in communication with hydrostatic pressure chamber. Communicating portion is blocked by spring sheet. The spring sheet is provided with optical fiber sensor. Hydrostatic pressure chamber is always in communication with seawater, and ambient water pressure chamber is always in communication with water in abyssal sedimentary layer. Releasing device includes electric winch provided with acoustic signal device. Base is provided with earth pressure sensor and weight member. Optical fiber sensor, acoustic signal device, and earth pressure sensor are connected with controller.

Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

Abstract: The present invention relates to a benzofuran derivative, a preparation method thereof and a use thereof in medicine. In particular, the present invention relates to the benzofuran derivative as shown by general formula (I), the preparation method thereof, a pharmaceutical composition containing the derivative, and uses thereof as an EZH2 inhibitor and in the prevention and/or treatment of diseases such as tumours and cancers, etc., and in particular, uses thereof in the prevention and/or treatment of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and synovial sarcoma, wherein the definitions of the substituents in the general formula (I) are the same as those defined in the description.

Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.

Abstract: The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as Raf kinase, especially BRAF kinase, inhibitors, which are useful therapeutic agents for treatment of Raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds.

Abstract: The present invention provides novel aminoisoquinoline compounds as defined in the specification, compositions thereof use of these compounds as protein kinase inhibitors and as therapeutic agents for treatment of Raf kinase, in particular BRAFV600E kinase, related diseases or disorders, such as cancers. In addition, the invention also includes methods and processes for preparing these novel aminoisoquinoline compounds.

Abstract: The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as Raf kinase, especially BRAF kinase, inhibitors, which are useful therapeutic agents for treatment of Raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds.